Print ISSN:-2249-8176

Online ISSN:-2348-7682

CODEN : PJMSD7

Current Issue

Year 2024

Volume: 14 , Issue: 2

  • Article highlights
  • Article tables
  • Article images

Article Access statistics

Viewed: 231

Emailed: 0

PDF Downloaded: 365


Satpathy, Mohanty, Routray, and Dash: Correlation of platelet indices with the spectrum of acute coronary syndrome and extent of coronary artery disease


Introduction

Platelets have a major role in acute coronary syndrome (ACS) and their activation is a hallmark of this. 1 Platelets have also been implicated in the pathogenesis of cardio-vascular disorders including atherosclerosis and its complications, such as acute myocardial infarction (AMI), unstable angina (UA) and sudden cardiac death. 2 They play a crucial role in thrombus formation after rupture of the atherosclerotic plaque. There will be increased release of larger platelets with denser granules that are highly active. 3 Though Trop I, Trop T and Creatine kinase enzymes are more sensitive and specific biomarkers of myocardial damage, they still are not enough sensitive at an early stage of ACS, remaining undetectable in about 40 – 60% of patients. 4 Platelet indices can be detected earlier, relatively in expensive, widely available and also easily recordable in most clinical laboratories. Hence platelet parameters can be better used as markers for possible benefitting in timely intervention in the emergency department by improving risk stratification. 5

The primary objective of this prospective observational study is to determine the correlation between platelet indices and the spectrum of ACS and to analyze if there exists a statistically significant difference between these indices and the numbers of vessels involved in patients admitted to the Cardiology ward and undergoing coronary angiogram.6, 7

Materials and Methods

This is a prospective observational study conducted on a tertiary care teaching hospital of eastern India over a period of six months from Jan 2018 to July 2018. 125 patients selected non-randomly with a diagnosis of ACS admitted to the Cardiology department who fulfilled the inclusion and exclusion criteria were enrolled for this study.

25 no of patients were excluded thereafter due to insufficient and unreliable data or withdrawal from voluntary consent.

Inclusion criteria

Patients > 18 years of age presenting with pain chest consistent with ACS with any of the following feature were added into the study population.

  1. Electrocardiographic (ECG Changes

    1. ST elevation

    2. ST depression

    3. T inversion.

  2. Trop T/Trop I /Creatine kinase MB isoform (CKMB elevation

Exclusion criteria

  1. Patients already on antiplatelet/anticoagulant therapy

  2. Patients with bleeding or clotting disorders.

  3. Patients with blood/platelet product transfusion within last 3 months.

  4. Primary platelet disorders, aplastic anemia.

  5. Pregnancy, sepsis

  6. Cancer, chronic kidney disease (CKD) with creatine clearance < 60 ml/min/m2body surface area (BSA).

  7. Advanced liver diseases.

  8. Patient on drugs that decreases cell count-Hydroxyurea, anti-neoplastic drugs.

  9. Severe left ventricular (LV) systolic dysfunction with ejection fraction (EF) <30%.

All the study participants after giving there informed consent were subjected to focus history taking and clinical examination to obtain information related to demographic profile, risk factor, presenting symptoms, vital recordings and baseline 12 lead ECG. Information documented in a predesigned data sheet.

For measuring platelet indices blood samples were taken at the time of admission before starting any specific treatment. 2 ml of blood taken on the Ethylene diamine tetra acetic acid (EDTA) vacutainers obtained via antecubital venous access, examined within 30 minutes (6) by a fully automatic bidirectional hematology analyzer (SYSMEX XN 100) on flow cytometry principle for complete blood count. Platelet parameters like total platelet count (TPC), mean platelet volume(MPV), platelet distribution width( PDW), platelet large cell ratio( P-LCR) and platelet-crit (PCT) were noted. Other regular blood investigations were also performed.

Selective coronary angiogram was performed by femoral or radial approach by expert cardiologist. Angiogram results were interpreted by two different cardiologists according to quantitative coronary angiogram (QCA) method. Diameter stenosis > 50% in epicardial coronary arteries was accepted as significant. Left main stenosis of more than 30% was included in triple vessel disease (TVD). In patients with typical pain chest of > 20 minutes duration ST elevated myocardial infarct (STEMI) was defined as > 2 mm ST segment elevation at the ‘J’ point in at least 2 consecutive ECG leads from V1 to V3 or > 1 mm elevation in other leads. Non ST elevated myocardial infarct (NSTEMI) was defined as any ECG changes other than STEMI and/or typical pain chest with positive cardiac biomarkers more than two fold of upper limit of normal values. Unstable angina defined as typical pain chest and/or any of the ECG changes with non-diagnostic cardiac biomarkers.

Statistical analysis

Statistical analysis was done using R version 3.6.3 for calculating mean and standard deviation (SD) of the continuous variables. Comparison of the data distribution between groups was done using Mann Whitney Wilcoxon test. P value of less than or equal to 0.05 was considered significant. Pearson’s correlation between the platelet indices was obtained using the Cor.test. Correlation coefficient of more than 0.7 was considered strong and less than 0.5 was considered weak relation.

Results

A total of 100 ACS patients were evaluated comprising of 78 STEMI patients, 18 NSTEMI patients and 04 UA patients. The age range of the patients was 27-75 years. The male patients compromised 87.4% of the study population. The base line characteristics of the study patients are summarized in Table 1.

Table 1

The base line characteristics of the study group

Parameters

Values

Age range

27-75 years

Male Population

87.4%

Female Population

12.6%

Hypertension

36%

Diabetes mellitus

40.8%

Smoking

28.8%

Body mass Index

24 +3.4 (mean + SD)

Ejection fraction

55.34 + 11.3%(mean + SD)

LDL(low density lipoprotein)

100 to 8 + 34.2 mg%(mean + SD)

HDL(high density lipoprotein)

40.9 + 8.9mg%(mean + SD)

TG(triglyceride)

160.2 + 92.3mg%(mean + SD)

STEMI

78%

NSTEMI

18%

UA

4%

Following coronary angiography the extent of coronary artery disease as per the number of vessels involved significantly by QCA method was as follows in Table 2.

All the Platelet parameters were found to be the highest in STEMI, followed by NSTEMI and the lowest in UA patients, but the values of P-LCR and PCT were significantly increased in STEMI only when compared to UA patients (P=0.05, P=0.03) Table 3.

Table 2

Extent of Coronary Artery Disease (CAD)

Number of Vessels involved

n (%)

Single vessel disease (SVD)

52 (52)

Double vessel disease (DVD)

28 (28)

Triple vessel disease (TVD)

20 (20)

Table 3

Comparison of platelet indices between different spectrums of ACS

Platelet Indices

STEMI (I) n(78) mean +SD

NSTEMI (II) n(18) mean +SD

UA (III) n(4) mean +SD

P Value(d)

A

b

C

MPV(fL)

11.74+1.76

11.29+2.70

10.5+4.44

0.76

0.78

1.0

PDW(fL)

15.02+3.58

14.56+4.38

14.24+5.92

0.74

0.93

0.93

TPC (x103/µL)

264.69+92.59

231+78.87

192.96+82.83

0.23

0.07

0.32

PLCR(%)

38.82+10.17

37.92+12.78

28.45+12.03

0.98

0.05d

0.08

PCT(%)

0.31+0.10

0.26+0.08

0.21+0.09

0.06

0.03d

0.27

[i] a - P value within group I and II

[ii] b- P Value within group I and III

[iii] c- P Value within group II and III

[iv] d- P value <0.05 was considered statistically significant.

Linear regression analysis performed to determine the Pearson’s correlation between one platelet parameter with others. Statistically very significant and strong positive correlation was observed amongst PDW, PLCR and MPV (r=0.9) (Table 4, Table 5, Table 6). Similarly TPC and PCT are very significantly related to each other with a strong positive correlation (r=0.9) (Table 7, Table 8). These relations are seen across the entire spectrum of ACS.

Table 4

Pearson Correlation (r) between PDW and other platelet indices in various spectrums of ACS

PDW Vs.

STEMI

NSTEMI

UA

TPC

r value

-0.45f

-0.24

0.09

p value

3.48E-05d

0.31

0.87

MPV

r value

0.91e

0.91e

0.96e

p value

2.20E-16d

3.25E-08d

0.003d

PLCR

r value

0.91e

0.97e

0.94e

p value

2.20E-16d

1.03E-12d

0.004d

PCT

r value

-0.32f

0.06

0.25

p value

4.42E-03d

8.11E-01

0.63

[i] d – P value of < 0.05 was considered statistically significant.

[ii] e – Pearson correlation co-efficient of >0.7 indicates strong relation.

[iii] f- Pearson correlation co-efficient of <0.5 indicates weak relation.

Table 5

Pearson Correlation (r) between PLCR and other platelet indices in various spectrums of ACS

PLCR Vs.

STEMI

NSTEMI

UA

TPC

r value

-0.39f

-0.35

0.39

p value

3.07E-04d

0.13

0.44

MPV

r value

0.86e

0.87e

0.99e

p value

2.20E-16d

7.62E-07d

0.000d

PDW

r value

0.91e

0.97e

0.94e

p value

2.20E-16d

1.03E-12d

0.005d

PCT

r value

-0.24f

-0.04

0.55

p value

3.18E-02d

8.68E-01

0.26

[i] d – P value of < 0.05 was considered statistically significant.

[ii] e – Pearson correlation co-efficient of >0.7 indicates strong relation.

[iii] f- Pearson correlation co-efficient of < 0.5 indicates weak relation.

Table 6

Pearson Correlation (r) between MPV and other platelet indices in various spectrums of ACS

MPV Vs.

STEMI

NSTEMI

UA

TPC

r value

-0.27f

0.06

0.38

p value

0.02d

0.80

0.46

PDW

r value

0.91e

0.91e

0.96e

p value

2.20E-16d

3.25E-08d

0.003d

PLCR

r value

0.86e

0.87e

0.99e

p value

2.20E-16d

7.62E-07d

0.000d

PCT

r value

-0.14

0.33

0.52

p value

2.08E-01

1.50E-01

0.29

[i] d – P value of < 0.05 was considered statistically significant

[ii] e – Pearson correlation co-efficient of >0.7 indicate strong relation

[iii] f- Pearson correlation co-efficient of <0.5 indicates weak relation

Table 7

Pearson Correlation (r) between TPC and other platelet indices in various spectrums of ACS

TPC Vs.

STEMI

NSTEMI

UA

MPV

r value

-0.27f

-0.06

0.38

p value

0.02d

0.80

0.46

PDW

r value

-0.45f

-0.24

0.09

p value

3.48E-05d

0.31

0.87

PLCR

r value

-0.39f

-0.35

0.39

p value

0.000d

0.13

0.44

PCT

r value

-0.92e

0.94e

0.98e

p value

2.20E-16d

4.84E-10d

0.000d

[i] d – P value of < 0.05 was considered statistically significant

[ii] e – Pearson correlation co-efficient of >0.7 indicates strong relation

[iii] f- Pearson correlation co-efficient of <0.5 indicates weak relation

Table 8

Pearson Correlation (r) between PCT and other platelet indices across various spectrums of ACS

PCT Vs.

STEMI

NSTEMI

UA

TPC

r value

0.87e

0.97e

0.91e

p value

1.74E-07d

2.20E-16d

2.20E-16d

MPV

r value

0.21

0.05

-0.04

p value

3.52E-01

8.00E-01

0.78

PDW

r value

-0.04

-0.18

-0.23

p value

8.46E-01

3.46E-01

0.09

PLCR

r value

-0.000

-0.16

-0.14

p value

9.99E-01

3.87E-01

0.31

[i] d – P value of < 0.05 was considered statistically significant

[ii] e – Pearson correlation co-efficient of >0.7 indicates strong relation

There was no significant difference of the platelet indices according to the number of vessels significantly involved by QCA method (Table 9).

Table 9

Comparison of platelet indices with different extent of CAD

Platelet Indices

SVD (I) n(52) mean +SD

DVD (II) n(28) mean +SD

TVD (III) n(20) mean +SD

P Value(d)

a

b

C

MPV(fL)

11.13+2.5

11.89+2.44

11.59+1.93

0.10

0.37

0.25

PDW(fL)

14.17+4.02

15.63+4.31

14.78+3.58

0.17

0.46

0.39

TPC (x103/µL)

238.90+81.06

243.31+93.94

260.59+87.30

0.96

0.27

0.31

PLCR(%)

35.36+10.13

41.06+12.08

37.60+10.52

0.06

0.40

0.15

PCT(%)

0.27+0.09

0.29+0.10

0.30+0.10

0.95

0.33

0.42

[i] a - P value within group I and II

[ii] b-P Value within group I and III

[iii] c-P Value within group II and III

[iv] d- P value <0.05 was considered statistically significant.

PDW, PLCR and MPV are very significantly related to each other with a strong positive association (r= 0.8 to 0.9) (Table 10, Table 11, Table 12). Similarly TPC and PCT are also very significantly related to each other with a strong positive association(r=0.9) (Table 13, Table 14). Both the relations are found irrespective of the extent of CAD (whether SVD, DVD or TVD).

Table 10

Pearson Correlation (r) between PDW and other platelet indices across various extent of CADd – P value of <0.05 was considered statistically significant

PDW Vs.

SVD

DVD

TVD

TPC

r value

-0.15

-0.35

-0.43f

p value

0.51

0.06

0.001d

MPV

r value

0.89e

0.91e

0.92e

p value

4.48E-08d

1.78E-12d

2.20E-16d

PLCR

r value

0.92e

0.94e

0.90e

p value

1.67E-09d

6.77E-15d

2.20E-16d

PCT

r value

-0.04

-0.18

-0.23

p value

8.46E-01

3.46E-01

8.74E-02

[i] e – Pearson correlation co-efficient of >0.7 indicates strong relation

[ii] f- Pearson correlation co-efficient of <0.5 indicates weak relation

Table 11

Pearson Correlation (r) between PLCR and other platelet indices across various extent of CAD

PLCR Vs.

SVD

DVD

TVD

TPC

r value

-0.13

0.35

-0.38f

p value

0.57

0.06

0.004d

MPV

r value

0.84e

0.87e

0.85e

p value

1.17E-06d

7.21E-10d

4.93E-16d

PDW

r value

0.92e

0.94e

0.90e

p value

1.67E-09d

6.77E-15d

2.20E-16d

PCT

r value

-0.0003

-0.16

-0.14

p value

9.99E-01

3.87E-01

3.11E-01

[i] d – P value of < 0.05 was considered statistically significant.

[ii] e – Pearson correlation co-efficient of >0.7 indicates strong relation.

[iii] f- Pearson correlation co-efficient of <0.5 indicates weak relation.

Table 12

Pearson Correlation(r) between MPV and other platelet indices across various extent of CAD

MPV Vs.

SVD

DVD

TVD

TPC

r value

0.16

-0.11

-0.21

p value

0.49

0.57

0.12

PDW

r value

0.89e

0.91e

0.92e

p value

4.48E-08d

1.78E-12d

2.20E-16d

PLCR

r value

0.84e

0.87e

0.85e

p value

1.17E-06d

7.21E-10d

4.93E-16d

PCT

r value

0.21

0.05

-0.04

p value

3.52E-01

8.00E-01

7.81E-01

[i] d – P value of < 0.05 was considered statistically significant

[ii] e – Pearson correlation co-efficient of >0.7 indicates strong relation

Table 13

Pearson Correlation (r) between PCT and other platelet indices across various extent of CAD

PCT Vs.

SVD

DVD

TVD

TPC

r value

0.87e

0.97e

0.91e

p value

1.74E-07d

2.20E-16d

2.20E-16d

MPV

r value

0.21

0.05

-0.04

p value

3.52E-01

8.00E-01

7.81E-01

PDW

r value

-0.04

-0.18

-0.23

p value

8.46E-01

3.46E-01

8.74E-02

PLCR

r value

-0.0003

-0.16

-0.14

p value

9.99E-01

3.87E-01

3.11E-01

[i] d – P value of < 0.05 was considered statistically significant.

[ii] e – Pearson correlation co-efficient of >0.7 indicates strong relation.

Table 14

Pearson Correlation (r) between TPC and other platelet indices across various extent of CAD

TPC Vs.

SVD

DVD

TVD

MPV

r value

0.16

-0.11

-0.21

   p value

0.49

0.57

0.12

PDW

r value

-0.15

-0.35

-0.43f

p value

5.13E-01

0.06

0.001d

PLCR

r value

-0.13

-0.35

-0.38f

p value

0.57

0.06

0.004d

PCT

r value

0.87e

0.97e

0.91e

p value

1.74E-07d

2.20E-16d

2.20E-16d

[i] d – P value of < 0.05 was considered statistically significant.

[ii] e – Pearson correlation co-efficient of >0.7 indicates strong relation.

[iii] f- Pearson correlation co-efficient of <0.5 indicates weak relation.

Discussion

Platelet activation favours thrombus formation and coronary artery occlusion thus playing a key pathogenic role in AMI. Platelets are also heterogeneous in terms of size, density and activity. Larger hyperactive platelets may play an important role in thrombus formation, resulting in acute thrombotic events. 8 Release of larger platelets from bone marrow could follow decrease of TPC due to their consumption at the site of thrombosis. 9 Thus these markers could maintain their strength and predictive value in ACS patients. Automated cell counters in hospital laboratories have made platelet indices available routinely and effortlessly as a byproduct, which can be added as a cost effective tool in diagnosis and prognosis of ACS spectrum and CAD extent.

In the present study we measured the platelet parameters in patients suffering from ACS with age range of 27-75 years comprising of 87.4% male and 12.6% females. In our study apart from P-LCR & PCT other platelet indices did not show a significant difference amongst various spectrum of ACS. This is comparable to the study, conducted by Gargi G et al. 10 The value of P-LCR was significantly increased in STEMI patients compared to UA patients. This is also comparable to the results of the study by Ranjith MP et al. 11 wherein PLCR was significantly higher in patients of ACS, compared to control population. This could be because P-LCR is another index of platelet volume. The study conducted by Sermin et al showed that MPV value of STEMI patients was slightly higher than NSTEMI patients but without reaching statistical significance. 12 Our study similarly showed MPV to be more in STEMI than NSTEMI and least in UA without any statistically significant difference. Our study also showed that TPC is highest in STEMI, followed by NSTEMI and least in UA, without intergroup statistical significance. Similar result was also observed by Dehghani et al, 13 where platelet count was 2.8% more in MI compared to UA but P was 0.16. So also in that study MI patients had significantly higher PLCR than UA, as seen in the present study.

We found statistically significant weak negative correlation within TPC and platelet volume indices, which was also seen by Bhawani YA et al. 4 Pearson correlation analysis done to determine the relation of the TPC with other platelet indices showed that it is having a negative but significant correlation with MPV and PDW in STEMI patients in the study by Reddy SK et al. 14 Similar to that our study shows that TPC is having significant negative correlation with all platelet volume indices in STEMI patients. But in TVD group this is restricted to PDW and PLCR but not MPV. Increased MPV and PDW are known to be associated with increased morbidity, mortality and recurrent MI. 15, 16 Thus they could be simple and reliable biomarkers to predict significant and severe coronary events. In the study by Dehghani et al Pearson correlation analysis done had shown that significant negative correlation exist between TPC and MPV or PLCR but not PDW (0.07) in MI patients. But here this relation is applicable to all volume indices in STEMI patients.

MPV value of more than 9.0 fL is usually defined as high. Though in patients of ACS, MPV is found to be high across the spectrums, there is no significant relation of severity of CAD with their MPV values. This was also seen by Reddy Sk et al. 14 In another large scale study by De Luca G et al 17 there was no correlation between MPV or PDW and the extent of CAD, according to coronary angiogram either in ACS or elective cases. Similarly in our study none of the volume indices is related to extent of CAD in angiography of ACS patients.

In the earlier largest study so far PWD was inversely related to TPC in a significant manner (P<0.001). Our study also showed significant negative correlation between PDW and TPC (P=0.001) but only in patients of TVD. But in STEMI patients this negative correlation was found for both TPC (P=3.48 E-05) and PCT (P=4.42 E-03).

Conclusion

Irrespective of the spectrum of ACS or extent of CAD, platelet volume indices are very significantly associated with each other in a strong positive way. Similarly TPC and PCT are having such aforementioned relation with each other. However though the study showed that PDW and MPV may not be related to the spectrum of ACS or to the CAD extent, increased value of PLCR and PCT seems to be independent risk factors for development of STEMI than UA. In addition in ACS patients TPC is having a mild negative but significant correlation with all platelet volume indices only in STEMI patients, but it has similar relation with only PDW and PLCR in TVD patients.

There simple, reliable, easy to perform, noninvasive and economic method may predict the risk of STEMI in ACS presentation, thus could serve as important tools for risk stratification in them.

But conflicting results of various platelet indices in difference studies emphasizes that further large scale trials should be conducted in future to include those simple platelet parameters in triaging of ACS patient management.

Limitations

This study had a smaller sample size and long term follow up was not done for prognostic evaluation of those parameters. Risk factors HT, DM, smoking and drugs like Atorvastasin, 18 Insulin, 19 nonsteroidal anti-inflammatory drugs (NSAIDS) and Caffeine, 20 could act as confounding factors. Furthermore IVUS could have provided more accurate information on the severity of CAD and plaque burden which could not be done in this study. Conventional cardiac biomarkers could also have been compared with platelet indices for better understanding of the process.

Acknowledgement

We are indebted to all the senior residents, nurses, technician and other paramedical staffs of our department and catheterization laboratory for their immense contribution and dedication for our patient treatment and clinical care.

Source of Funding

No financial support was received for the work from any external source. Self-funding only done for the hematological study.

Conflict of Interest

None.

References

1 

C N Kilicli R Demirtune C Konuralp A Eskiser Y Basaran Could MPV be a predictive marker for AMI?Med Sci monit2005118CR38792

2 

G Endler A Klimesch P H Sunder M Schilliger M Exner C Mannhalter MPV is an independent risk factor for MI but not CADBr J Haemotol2002117239940410.1046/j.1365-2141.2002.03441.x

3 

R Pal R Bagarhatta S Gulati M Rathore N Sharma MPV in patients with ACS. a supportive diagnostic predictorJ Clin Diagn Res2014881410.7860/JCDR/2014/8394.4650

4 

G Lippi M Montagnana GL Salvagno GC Guidi Potential value for new diagnostic markers in the early recognition of ACSCJEM200681273110.1017/s148180350001335x

5 

J Manchanda RM Potekar S Badiger A Tiwari The study of platelet indices in ACSAnn Pathol Lab Med201521305

6 

M D Lance R Van Oerle Y M Henskens M A Marcus Do we need time adjusted MPV measurements?Lab Hematol20101632831

7 

K Thygesen J S Alpert H D White Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction; Universal definition of myocardial infarctionEu HeartJ2007282025253810.1093/eurheartj/ehm355

8 

A Mathur MS Rokinson J Cotton JF Martin JD Erusalimsky Platelet reactivity in ACS. Evidence for differences in platelet behavior between UA and MIThromb Haemost200185698994

9 

E Yetkin MPV not so far from being a routing diagnostic and prognostic measurementThromb Haemostat200810013410.1160/TH08-05-0336

10 

G Gargi A Saini A Sharma P Jaret Mean platelet volume in acute coronary syndrome: Diagnostic implicationsHeart India201864123610.4103/heartindia.heartindia_17_18

11 

M Ranjith R Divya V Mehta M Krishnan R Kamalraj A Kavishwar Significance of platelet volume indices and platelet count in IHDJ Clin Pathol2009629830310.1136/jcp.2009.066787

12 

S Yekeler K Akay F Borlu Comparison of MPV and PLT values in patients with and without diagnosis of ACSJ.Am Coll Cardiol20136218-S2116

13 

MR Dehghani LT Sani Y Rezai R Rostami Diagnostic importance of admission platelet volume indices in patients with acute chest pain suggesting ACSIndian Heart J2014666622810.1016/j.ihj.2014.10.415

14 

S K Reddy R Shetty S Marupuru N Yedavalli K Shetty Significance of platelet volume indices in STEMI patients. A case control studyJ Clin Diagn Res201711457

15 

SG Chu RC Becker RC Becker PB Berger DL Bhatt JM Eikelboon MPV as predictor of cardiovascular risk. A systemic review and metaanalysisJ Thromb Haemostat2010811485610.1111/j.1538-7836.2009.03584.x

16 

B Y Alvitigala MAF Azra D U Kottahachchi MMPT Jayasekera RANK Wijesinghe A study of association between platelet volume indices and ST elevation MI201821710IJC Heart and vasculature

17 

G De Luca L Venegoni S Lorio G G Secco E Cassetti M Verdoia PDW and extent of CAD: Results from a large prospective studyPlatelets201021750814

18 

F Akin B Ayca N Kose I Sahin MN Akin TD Canbek Effect of Atorvastatin on hematologic parameters in patients with hypercholesterolemiaAngiology20136486215

19 

N Papanas G Symenoids E Maltezos G Mavridis E Karavageli T Vosnakidis MPV in patients with type2 Diabetes mellitusPlatelets20041584758

20 

P Harrison I Mackie A Mumford C Briggs R Liesner M Winter Guidelines for the laboratory investigation of heritable disorders of platelet functionBr J Haematol201115513044



jats-html.xsl

© 2022 Published by Innovative Publication Creative Commons Attribution 4.0 International License (creativecommons.org)